

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1093)**

### **INSIDE INFORMATION**

#### **PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2022**

This announcement is made by CSPC Pharmaceutical Group Limited (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

CSPC Innovation Pharmaceutical Co., Ltd. (“**CSPC XNW**”) is a subsidiary of the Company and its shares are listed on the ChiNext of Shenzhen Stock Exchange (Stock Code: 300765). In compliance with the relevant requirements of Shenzhen Stock Exchange, CSPC XNW published its 2022 First Quarterly Report for the three months ended 31 March 2022 on the information disclosure webpage of Shenzhen Stock Exchange’s website at <http://www.szse.cn/disclosure/listed/notice/index.html>.

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the appendices of this announcement (the “**Appendices**”) which set out the principal financial information of CSPC XNW prepared in accordance with the PRC Accounting Standard for Business Enterprises for the three months ended 31 March 2022.

Please note that the information in the Appendices is an extract of the unaudited financial statements prepared in Chinese. In case of any inconsistency between the Chinese version and the English version, the Chinese version shall prevail.

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 29 April 2022

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.*

**APPENDIX I**  
**PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS**

*Unit: RMB*

	<b>Current reporting period</b>	<b>Corresponding reporting period of last year</b>	<b>Increase/decrease compared with the corresponding reporting period of last year</b>
Revenue (Yuan)	447,222,824.66	357,139,832.90	25.22%
Net profit attributable to listed company's shareholders (Yuan)	110,992,466.52	83,862,300.22	32.35%
Net profit attributable to listed company's shareholders less the non-recurring gain/loss (Yuan)	111,537,005.48	77,725,407.02	43.50%
Net cash flows arising from operating activities (Yuan)	70,514,173.43	48,579,724.40	45.15%
Basic earnings per share (Yuan/share)	0.2033	0.1536	32.36%
Diluted earnings per share (Yuan/share)	0.2033	0.1536	32.36%
Weighted average return on net assets	3.69%	3.08%	0.61%
	<b>End of the current reporting period</b>	<b>End of last year</b>	<b>Increase/decrease compared with the end of last year</b>
Total assets (Yuan)	3,350,339,318.61	3,225,776,209.68	3.86%
Equity attributable to listed company's shareholders (Yuan)	3,063,412,542.03	2,952,078,874.74	3.77%

## APPENDIX II

### NON-RECURRING GAIN/LOSS ITEMS AND AMOUNTS

*Unit: RMB (Yuan)*

Items	Amount for current reporting period	Description
Gain/loss from disposal of non-current assets (including the part offset with the provision for impairment of assets)	-3,600,178.53	
Government grants recognised in profit or loss of current period (excluding those closely related to the Company's normal operating business and continuously granted according to certain quota of amount or volume under national policies)	688,952.24	
Except for the effective hedging activities related to the company's normal operating business, profit or loss arising from changes in the fair value of financial assets held for trading and financial liabilities held for trading, and investment income from the disposal of financial assets held for trading, financial liabilities held for trading and financial assets held for sales	2,164,124.48	
Non-operating income and expenses other than the above items	216,573.13	
Less: Impact of income tax	14,072.05	
Impact of minority interests (after tax)	-61.77	
<b>Total</b>	<b>-544,538.96</b>	—

## APPENDIX III

### DETAILS AND REASONS FOR SIGNIFICANT CHANGES IN MAJOR ACCOUNTING DATA AND FINANCIAL INDICATORS

#### 1. Major Consolidated Balance Sheet Items

*Unit: RMB (Yuan)*

Items	31 March 2022	31 December 2021	Percentage change	Analysis on the reasons for changes
Bank balances and cash	1,702,759,601.87	1,231,863,277.33	38.23%	Mainly due to the increase in sales receipts as a result of growth in business and the redemption of structured deposits upon maturity.
Financial assets held for trading	0.00	413,594,150.88	-100.00%	Due to the redemption of structured deposits upon maturity.
Deferred income tax assets	17,248,396.88	11,834,518.27	45.75%	Mainly due to temporary differences arising from the unrealized gains and losses of internal sales on consolidation.
Tax payables	31,385,737.02	17,870,058.86	75.63%	Mainly due to the increase in income tax and value-added tax payables at the end of the reporting period.

## APPENDIX III

### DETAILS AND REASONS FOR SIGNIFICANT CHANGES IN MAJOR ACCOUNTING DATA AND FINANCIAL INDICATORS

#### 2. Major Consolidated Income Statement Items

*Unit: RMB (Yuan)*

Items	January-March 2022	January-March 2021	Percentage change	Analysis on the reasons for changes
Cost of sales	225,955,532.18	149,449,014.49	51.19%	Mainly due to an increase in the cost of caffeine products resulting from an increase in the cost of raw materials.
Tax and surcharge	2,701,857.26	4,565,919.08	-40.83%	Mainly due to the city construction tax and education surcharge.
Selling expenses	67,813,066.80	98,621,509.13	-31.24%	Mainly due to a decrease in the marketing expenses of the company's health food products.
Research and development expenses	5,898,007.24	2,412,933.50	144.43%	Mainly due to an increase in the company's investments in research and development.
Finance expenses	-4,709,179.88	-3,235,373.69	-45.55%	Mainly due to an increase in the company's interest income.
Income from change in fair value	0.00	3,932,830.86	-100.00%	Due to the redemption of structured deposits upon maturity.
Non-operating expenses	3,666,671.27	572,424.14	540.55%	Mainly due to the write-off of fixed assets by the company.
Income tax expenses	25,006,869.40	17,939,649.21	39.39%	Mainly due to an increase in the company's revenue.
Net profit	110,974,787.52	83,528,243.63	32.86%	Mainly due to a growth in performance of the company's caffeine products. During the reporting period, caffeine products achieved a revenue of RMB331,219.5 thousand, representing an increase of 65.32% as compared to the corresponding period last year.

**APPENDIX III**  
**DETAILS AND REASONS FOR SIGNIFICANT CHANGES IN**  
**MAJOR ACCOUNTING DATA AND FINANCIAL INDICATORS**

**3. Major Consolidated Cash Flow Statement Items**

*Unit: RMB (Yuan)*

Items	January-March 2022	January-March 2021	Percentage change	Analysis on the reasons for changes
Net cash flows generated from operating activities	70,514,173.43	48,579,724.40	45.15%	Mainly due to an increase in cash received from sale of goods or rendering of services resulting from a growth in the company's performance.
Net cash flows generated from investment activities	400,463,086.80	105,255,652.62	280.47%	Mainly due to the redemption of structured deposits purchased in 2021 during the reporting period upon maturity, resulting in an increase in cash received from investment.
Net increase in cash and cash equivalents	470,896,324.54	153,950,372.19	205.88%	Mainly due to the redemption of structured deposits purchased with idle proceeds upon maturity, resulting in a higher bank balance than that of the corresponding reporting period of last year.